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Background and aims: The aim of this study was to investigate the genetic aetiology of intrahepatic
cholestasis of pregnancy (ICP) and the impact of known cholestasis genes (BSEP, FIC1, and MDR3) on
the development of this disease.
Patients and methods: Sixty nine Finnish ICP patients were prospectively interviewed for a family his-
tory of ICP, and clinical features were compared in patients with familial ICP (patients with a positive
family history, n=11) and sporadic patients (patients with no known family history of ICP, n=58). For
molecular genetic analysis, 16 individuals from two independently ascertained Finnish ICP families
were genotyped for the flanking markers for BSEP, FIC1, and MDR3.
Results: The pedigree structures in 16% (11/69) of patients suggested dominant inheritance. Patients
with familial ICP had higher serum aminotransferase levels and a higher recurrence risk (92% v 40%).
Both segregation of haplotypes and multipoint linkage analysis excluded BSEP, FIC1, andMDR3 genes
in the studied pedigrees. Additionally, the MDR3 gene, previously shown to harbour mutations in ICP
patients, was negative for mutations when sequenced in four affected individuals from the two families.
Conclusions: These results support the hypothesis that the aetiology of ICP is heterogeneous and that
ICP is due to a genetic predisposition in a proportion of patients. The results of molecular genetic
analysis further suggest that the previously identified three cholestasis genes are not likely to be impli-
cated in these Finnish ICP families with dominant inheritance.
Intrahepatic cholestasis of pregnancy (ICP) is a cholestaticdisorder which complicates otherwise normal pregnancies.The diagnosis is based on elevated serum levels of bile acid
and aminotransferases, and on the presence of pruritus. ICP
causes no risk to the mother but it increases the risk of
preterm delivery and fetal loss.1 In 0.5–3.5% of ICP cases, the
fetus dies suddenly for unknown reasons.2–4
The aetiology of ICP is not known but MDR3 mutations have
recently been identified in two families: one with progressive
familial intrahepatic cholestasis (PFIC) and ICP5 and another
with a single patient with ICP.6 Obligate carriers of PFIC1 and
PFIC2 have also been reported to have experienced ICP.7–9
Familial clustering and uneven geographical distribution also
indicate the genetic basis of the disease. In Scandinavian
countries, ICP occurs in 0.5–1.8% of all pregnancies,10 11 in
Canada and Western Europe in 0.1–0.2%,12 while in Chile the
reported incidence in pregnancies of women of Araucanian
Indian origin is as high as 22%.13 The direct parent to child
transmission of ICP suggests dominant inheritance, either
autosomal or X linked.14–16
The prevalence of cholelithiasis is known to be higher in ICP
patients than in the normal population.17 18 This finding was
further strengthened by the recent identification of MDR3
mutations in patients with cholesterol cholelithiasis.19
While the aetiology of ICP is not known, other inherited
cholestatic conditions are caused by known gene defects.20–22
Progressive familial intrahepatic cholestasis type 1 (PFIC1) is
an autosomal recessive disease characterised by defective bil-
iary secretion of bile acids and was first described in patients
of Amish ancestry.7 It starts in infancy and necessitates liver
transplantation in the first decade of life. The FIC1 gene
(ATPase class I type 8B (ATP8B1)) underlying the disease is
located on chromosome 18q21.8 The protein encoded by this
gene probably functions as a canalicular P type ATPase that
participates in maintaining the distribution of aminophos-
pholipids between the inner and outer leaflets of the plasma
membrane.23 Recurrent familial intrahepatic cholestasis (be-
nign recurrent intrahepatic cholestasis (BRIC)) is character-
ised by recurrent attacks of cholestasis but without progres-
sion to chronic liver disease. Consistent with PFIC1,
gammaglutamyl transferase (γ- GT) is not increased. The gene
involved in this disease was also mapped to chromosome
18q2124 and the gene (ATP8B1) causing PFIC1 disease was
subsequently shown to be mutated in BRIC patients.22 A
canalicular bile acid transport pump is defective in patients
with PFIC type 2 (PFIC2).25 The BSEP (bile salt export pump)
gene, also called ATP binding cassette subfamily B member 11
(ABCB11), underlying this disease is located on chromosome
2q24. It encodes a canalicular bile salt export pump, a
P-glycoprotein belonging to class B of the ABC transporter
super family.
PFIC type 3 (PFIC3) is characterised by defective biliary
secretion of phospholipids. Bile becomes toxic because of the
lack of phospholipids and therefore causes liver damage. The
gene underlying this disease is MDR3 (or P-glycoprotein 3,
PGY3) on chromosome 7q21.26 27 Serum γ-GT activity, a differ-
ential marker for a MDR3 defect versus FIC1 or BSEP defects,
is markedly elevated in these patients. Although symptoms
present later in life in PFIC3 than in PFIC1 and PFIC2, liver
transplantation is eventually needed. Two reported families
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with PFIC3 also have ICP.5 Children with PFIC3 are
homozygous for mutations in the MDR3 gene while their
heterozygous mothers have ICP. One ICP patient with raised
serum γ-GT but without a known family history of PFIC has
been reported to carry a trafficking mutation in the MDR3
gene.6
SUBJECTS AND METHODS
Subjects and samples
All women with ICP attending the Department of Obstetrics
and Gynecology, Helsinki University Central Hospital, be-
tween 5 March 1992 and 14 April 1993, and fulfilling the study
criteria for ICP (serum aspartate aminotransferase (ASAT)
>35 U/l, serum alanine aminotransferase (ALAT) >35 U/l,
and/or serum bile acid values >8 mol/l with itching, or serum
bile acid values >8 mol/l with or without itching and negative
for hepatitis B (HBV) and C (HCV) virus using HBV surface
antigen (HBsAg) and HCV antibody testing) were prospec-
tively interviewed for occurrence of ICP and cholelithiasis in
first, second, and third degree relatives. The diagnoses of the
reported cases of ICP were confirmed from the hospital
records. Data on occurrence of cholelithiasis or other liver dis-
eases were recorded according to information provided by the
patients. Also, data on previous use of the contraceptive pill
were collected.
Each ongoing pregnancy was evaluated for clinical symp-
toms and laboratory tests and the two highest ASAT, ALAT, bile
acid, and bilirubin values during pregnancy and after delivery
were recorded. Upper abdomen ultrasound examination was
performed to determine if the patient had gall stones. In addi-
tion, all relevant clinical variables such as gestational age,
birth weight, mode of delivery, and perinatal morbidity were
registered for each pregnancy.
Patients with a verified family history of ICP were classified
as familial ICP (fig 1) while those without a family history (or
for whom the family history could not be verified) were
termed sporadic cases. Data were analysed in these two groups
of patients. Probability values were calculated using the χ2 and
Student’s t test for enumeration and measurement data,
respectively. Yates’ correction was used where there was one
degree of freedom in the χ2 test. Values of p<0.05 were
considered significant.
Two multiplex families with ICP were independently ascer-
tained (pedigrees are shown in fig 2). These included 15
affected and six unaffected individuals from whom venous
blood (20 ml) was collected after informed consent. DNA was
extracted using standard methods.
Genotyping
Each individual from the two families depicted in fig 2 was
genotyped for the DNA microsatellite markers D2S2190 and
D2S111 flanking the BSEP locus, D7S644 and D7S2410 flank-
ing the MDR3 locus, and D18S977 (an intragenic marker) and
D18S849 flanking the FIC1 locus. The markers were chosen
from the GDB database including Marshfield and Genethon
markers. In all cases the forward primer was modified at the 5′
end with a FAM, TET, or HEX fluorescent label.
Polymerase chain reactions (PCR) were performed under
the following conditions: 50 ng genomic DNA, 1×buffer
(Applied Biosystems, Roche, Branchburg, New Jersey, USA),
10 mM deoxynucleotidetriphosphates (dNTPs), 5 pmol of
both the forward and reverse primer, and 0.75 U AmpliTaq-
Gold polymerase (Applied Biosystems) in a final volume of
15 µl. The initial denaturation at 94°C for 10 minutes was fol-
lowed by 30 cycles (FAM and TET markers) or 35 cycles (HEX
markers) at 94°C for 30 seconds, 55°C for 75 seconds, and 72°C
for one minute, followed by a final elongation step at 72°C for
10 minutes. Amplified products were separated by electro-
phoresis on a 4.25% polyacrylamide-6 M urea gel by a 377
DNA sequencer apparatus (Applied Biosystems) and the
results were processed by GENESCAN version 2.0.2 and
GENOTYPER version 1.1 software.
Linkage and haplotype analysis
Using the simulation program SLINK,28 families 1 and 2 (fig 2)
were estimated to give a maximum two point logarithm of
odds (LOD) score of 1.47 and 1.99, respectively (recombina-
tion fraction [θ]=0.00, marker heterozygosity=0.7, autosomal
dominant model with penetrance=85% and phenocopy
rate=1.1%). We used the GENEHUNTER 2 program27 to calcu-
late multipoint LOD scores across the BSEP, FIC1, and MDR3
regions, using the same assumptions as in the simulation
study and a population frequency of 0.002 for the disease
allele assumed on the basis of our own results. The allele fre-
quencies of the polymorphic markers were assumed to be
equal.
MDR3 gene sequencing
For mutational analysis of the MDR3 gene, four patients (two
individuals from each of the pedigrees in fig 2) were analysed
together with a normal control individual. Twenty seven pairs
of exon specific primers had been designed for a previous
study using long range PCR products covering parts of the
MDR3 gene and published sequence information.6 The primers
were utilised to amplify the 27 coding exons of the MDR3 gene
together with the respective exon/intron boundaries. Amplifi-
cation of genomic DNA by PCR was carried out using an auto-
mated DNA thermal cycler (MJ Research Tetrad, Genetics
Research Instrumentation Ltd, Felstead, Essex, UK) in a total
volume of 50 µl containing 50–100 ng DNA template, 100 ng
of each oligonucleotide primer, 50 mM KCl, 10 mM Tris/HCl,
pH 8.3, 1–3 mM MgCl2, 0.01% gelatin, 100 mM dNTP, and 2
units Taq polymerase (Bioline, London, UK). Reaction condi-
tions were as follows: 96oC for three minutes, 35 cycles of 30
seconds at 94oC, 30 seconds at 55–62oC, and one minute at
72oC, followed by a final extension for 10 minutes at 72oC. Fol-
lowing amplification, products were gel purified and se-
quenced using the MDR3 specific primers and the FS+ Dye
Figure 1 Eleven pedigrees with familial occurrence of intrahepatic
cholestasis of pregnancy.
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Terminator sequencing kit (PE Applied Biosystems) according
to the manufacturer’s instructions. Products were resolved
and the sequence determined using a 373XL semi automated
sequencer (PE Applied Biosystems), and the sequence
analysed utilising the Sequence Analysis, Sequence Navigator,
and AutoAssembler software packages (PE Applied Biosys-
tems).
RESULTS
In total, 69 pregnant women with ICP were studied. During
the study period there were 5304 deliveries in the study hos-
pital, giving an ICP incidence of 1.3 % (69/5304). The
incidence of multiple pregnancies was 2.8% (149/5304) in all
deliveries and 36% (25/69) in patients with ICP. The incidence
of ICP was 14% (19/137) in twin pregnancies and 43% (6/14)
in triplets.
The average age of ICP patients when interviewed was 31
years 9 months. Of these, 46% (32/69) were first pregnancies
while 54% (37/69) of patients had one or more previous deliv-
eries. A positive family history of ICP was verified in 16% of
patients (11/69) (fig 1) while 84% (58/69) of patients did not
have relatives diagnosed with ICP, did not have any knowledge
of it, or the information given by the patient could not be con-
firmed. The incidence of ICP among sisters of patients was
12% (6/49). Of 69 patients, 38 (55%) reported a positive fam-
ily history for cholelithiasis. There was no significant family
history of other liver diseases. In total, 57 of 69 patients had
used the contraceptive pill. Of these, 6/57 (11%) reported
elevated transaminase levels.
In clinical evaluations, 87% (60/69) of patients had itching.
In 98% of these cases, symptoms appeared during the third
trimester, after the 27th gestational week. Most patients (84%,
Figure 2 Two Finnish families with
intrahepatic cholestasis of pregnancy
in which linkage studies were
performed. The alleles for the markers
D2S2190, D2S111, D7S644,
D7S2410, D18S977, and D18S849
are shown for each genotyped
individual.
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57/68) had both elevated aminotransferase and bile acid
values. Eight per cent of those who had bilirubin values
measured (4/51) were hyperbilirubinaemic (>18 µmol/l)
while none of the patients was icteric.
While both serum ASAT (p<0.001) and ALAT (p<0.014)
values were higher in the familial than in the sporadic group
(table 1), bile acid values showed no significant difference
between the two groups. Cholelithiasis was diagnosed with
ultrasound, or cholecystectomy had been performed in 22%
(14/65) of cases. The percentage of patients with cholelithiasis
or who had undergone cholecystectomy was 30% (3/10) in the
familial and 20% (11/55) in the sporadic group. The overall
recurrence rate of ICP was 51% (29/57). There was a
statistically significant difference between the occurrence of
ICP in previous pregnancies of familial (92%, 11/12) and spor-
adic (40%, 18/45) patients. The corresponding values for
singleton pregnancies only were 100% (9/9) and 58% (19/33),
respectively. Of the multiple pregnancies, 88% (22/25)
occurred in the sporadic group.
The pedigrees and haplotypes of the two families in which
linkage analysis was performed are shown in fig 2. The
distance between the flanking markers D2S2190 and D2S111
at the BSEP locus on chromosome 2q24 is 4.8 cM. Multipoint
linkage analysis yielded positive LOD scores over this region in
family 2, with a maximum 1.12, while the results were nega-
tive in family 1. In haplotype analysis, the affected individuals
in family 1 had inherited different alleles, further excluding
BSEP in family 1.
The distance between the markers flanking the MDR3 gene
on chromosome 7q21 (D7S644, D7S2410) is 2.9 cM. The total
LOD scores were negative across the interval (table 2). As
MDR3 has previously been implicated in ICP,5 6 we sequenced
two patients from both families (see fig 2) but no mutations
were identified.
The distance between the flanking markers D18S977 and
D18S849 in the FIC1 region on chromosome 18q21 is 1.5 cM.
Multipoint linkage analysis in this interval yielded clearly
negative LOD scores. In both families affected family members
had differing haplotypes.
DISCUSSION
The frequency of ICP varies widely in different populations.
We found ICP in 1.3% of pregnancies which coincidences with
previous reports from Finland10 16 It is possible that this is an
underestimation of the actual incidence of ICP if all cases are
not diagnosed. However, in Finland this would be unlikely as
serum aminotransferase levels are routinely measured if a
patient has itching, in multiple pregnancies, and in patients
with a history of ICP or itching in a previous pregnancy. If
aminotransferase levels are elevated, the patient is referred to
the same maternity hospital (according to the residential
address) in which the patient would deliver in the case of an
uneventful normal pregnancy. This study was performed in
one of these hospitals in the Helsinki area.
The high incidence of multiple pregnancies (36%) and
increasing incidence of ICP in twin (14%) and triplet (43%)
pregnancies support the current view of multiple pregnancy
being a risk factor for ICP. In fact, this may be the only predis-
posing factor in some patients while ICP may be more likely to
occur in singleton pregnancies in patients with an inherited
predisposition.
ICP occurred in at least two close relatives in 11 of 69 (16%)
families. Only those in whom the family history could be veri-
fied from hospital records were accepted as familial. However,
it is likely that some familial cases were missed, as it was not
possible to confirm the diagnosis of ICP in pregnancies prior to
the late 1960s. Therefore, 16% is the minimum proportion of
familial cases and this number may actually be higher.
Several differences in clinical features were noted between
familial and sporadic cases. Familial cases had significantly
higher serum transaminase levels and, in particular, a higher
frequency of ICP (92% v 40%) in previous pregnancies. These
differences in phenotype may reflect a difference in the
underlying aetiology of ICP in the two groups. However, as
there are no definite tests to identify familial ICP, one would
expect some of the familial cases to be identified as
sporadic—that is, due to inheritance of the risk allele through
males in previous generations. Therefore, it may not always be
possible to show clearcut differences between the two groups,
even if they existed.
Table 1 Two highest ASAT, ALAT, and bile acid values, and comparison of clinical
features of ICP between familial and sporadic cases
Normal range Familial (n=11) Sporadic (n=58)
ASAT(U/l) 15–35 265.0 (66.0) 106.0 (9.0)**
ALAT (U/l) 10–40 348.7 (85.5) 190.5 (22.3)**
Bile acid (µmol/l) <6 29.4 (4.8) 32.0 (4.4)
No of multiple pregnancies 149/5304 (2.8%) 3/11 (27%) 22/58 (38%)
Occurence of ICP in previous pregnancies 11/12 (92%) 18/45 (40%)**
Values are mean (SEM) or number (%).
**Statistically significant.
ICP, intrahepatic cholestasis of pregnancy; ASAT, serum aspartate aminotransferase; ALAT, serum alanine
aminotransferase.
Table 2 Multipoint linkage analysis in two Finnish ICP pedigrees
Distance (cM)
BSEP MDR3 FIC1
D2S2190
(0.0) 2.40
D2S111
(4.80)
D7S644
(0.0) 1.45
D7S2410
(2.9)
D18S977
(0.0) 0.75
D18S849
(1.5)
LOD score family 1 −0.26 −0.23 −0.24 −1.09 0.43 0.73 −1.25 −1.24 −1.24
LOD score family 2 1.12 1.06 1.00 −1.38 −1.38 −1.40 −1.86 −1.86 −1.86
Total LOD score 0.86 0.83 0.76 −2.47 −0.95 −0.67 −3.11 −3.10 −3.10
ICP, intrahepatic cholestasis of pregnancy; BSEP, bile salt export pump gene; FIC1, familial intrahepatic cholestasis 1 gene; MDR3, multiple drug
resistance 3 gene; LOD score, logarithm of odds score.
LOD scores were calculated using the Genehunter 2.0 version.
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The prevalence of cholelithiasis was 22% in ICP patients.
While there are no data on the prevalence of cholelithiasis in
healthy women of reproductive age in Finland, studies from
Denmark and Norway reported a prevalence of 4.8–15.3%.30 31
Thus the higher frequency among ICP patients in this study
also suggests an association between ICP and
cholelithiasis.14–16 Interestingly, 55% of patients had relatives
who had been diagnosed with cholelithiasis or were cholecys-
tectomised. Additionally, several male relatives of index
patients were affected with cholelithiasis and cholelithiasis
was more frequent in the familial than in the sporadic group.
Therefore, cholelithiasis may be another expression of liver
dysfunction causing ICP, as suggested by the recent finding of
MDR3 mutations in patients with ICP and in patients with
cholesterol cholelithiasis.19
The dominant mode of inheritance of ICP, either autosomal
or X linked, has been proposed.14–16 The lacking male
phenotype, incomplete penetrance, and existence of ICP only
in pregnant women all complicate the study of inheritance of
ICP. Of the 11 familial cases, pedigrees 1, 2, and 3 showed typi-
cal dominant inheritance. In the other eight pedigrees, domi-
nant inheritance was possible considering the unknown male
phenotype and incomplete penetrance although they did not
clearly display the pattern. The two large pedigrees in which
linkage studies were performed both showed clear dominant
inheritance (fig 2). However, it is not possible to exclude X
linked inheritance by showing male to male transmission in a
female limited disease.
Linkage and haplotype analysis of BSEP, FIC1, and MDR3
loci did not indicate that these genes were implicated in the
Finnish ICP families. In family 1, linkage analysis of the
flanking markers around the BSEP gene yielded negative LOD
scores and inheritance of different haplotypes from the
affected mother to her affected descendants further excluded
the involvement of the BSEP gene in this family, although
slightly positive LOD scores were found in family 2. The FIC1
gene was clearly excluded by both haplotype and linkage
analysis in Finnish ICP patients. The negative total LOD scores
indicate exclusion of the MDR3 gene, as do the results of
sequence analysis which were negative for mutations when
four affected individuals from the two families were studied.
In conclusion, the aetiology of ICP appears to be hetero-
geneous. At least in 16% of cases ICP is familial and therefore
likely to be caused by an inherited predisposition, which is
dominantly inherited. The present data suggest that MDR3
and two other genes (FICI, VSEP) causing cholestatic
conditions are not likely to be involved in Finnish ICP families
and that other unknown genes may underlie ICP.
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